Your Trusted Brand for Over 35 Years

DHEA Restoration Therapy References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Hauffa BP, Kaplan SL, et al. Dissociation between plasma adrenal androgens and cortisol in Cushing's disease and ectopic ACTH-producing tumour: relation to adrenarche. Lancet . 1984 Jun 23;1(8391):1373-6.
  2. Valenti G. Adrenopause: an imbalance between dehydroepiandrosterone (DHEA) and cortisol secretion. J Endocrinol Invest . 2002;25(10 Suppl):29-35.
  3. Valenti G, Denti L, et al. Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study. J Gerontol A Biol Sci Med Sci . 2004 May;59(5):466-72.
  4. Pavlov EP, Harman SM, et al. Responses of plasma adrenocorticotropin, cortisol, and dehydroepiandrosterone to ovine corticotropin-releasing hormone in healthy aging men. J Clin Endocrinol Metab . 1986 Apr;62(4):767-72.
  5. Nafziger AN, Bowlin SJ, et al. Longitudinal changes in dehydroepiandrosterone concentrations in men and women. J Lab Clin Med . 1998 Apr;131(4):316-23.
  6. Orentreich N, Brind JL, et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab . 1984 Sep;59(3):551-5.
  7. LaCroix AZ , Yano K, et al. Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation . 1992 Nov;86(5):1529-35.
  8. Hornsby PJ. Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann NY Acad Sci . 1995 Dec 29;774:29-46.
  9. Belanger A, Candas B, et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J CLin Endocrinol Metab . 1994;79:1086-1090.
  10. Dzugan SA , Arnold Smith R . Hypercholesterolemia treatment: a new hypothesis or just an accident? Med Hypotheses. 2002 Dec;59(6):751-6.
  11. Khorram O, Vu L, et al. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol A Biol Sci Med Sci . 1997 Jan;52(1):M1-M7.
  12. James K, Premchand N, et al. IL-6, DHEA and the ageing process. Mech Ageing Dev . 1997 Feb;93(1-3):15-24.
  13. Straub RH, Konecna L, et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab . 1998 Jun;83(6):2012-7.
  14. Straub RH, Lehle K, et al. Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumour necrosis factor. Eur J Endocrinol . 2002 Mar;146(3):365-74.
  15. Leowattana W. DHEA(S): the fountain of youth. J Med Assoc Thai . 2001 Oct;84(Suppl 2):S605-S612.
  16. Sullivan KE. The Complex Genetic Basis of Systemic Lupus Erythematosus. Lupus Found Am Lupus News. 1999 Fall;19(4); 1999-2000 Winter;20(1). Available at Accessed May 24, 2005.
  17. van Vollenhoven RF, Morabito LM, et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol . 1998 Feb;25(2):285-9.
  18. Chang DM, Lan JL. et al. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum . 2002 Nov;46(11):2924-7.
  19. Lock M. Menopause in cultural context. Exp Gerontol. 1994 May-Aug;29(3-4):307-17.
  20. Braunstein GD. Androgen insufficiency in women: summary of critical issues. Fertil Steril. 2002;77(4):S94-S99.
  21. Belaisch J . DHEA: desire and resistance. Gynecol Obstet Fertil . 2002 Dec;30(12):961-9.
  22. Stomati M, Monteleone P, et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol . 2000 Oct;14(5):342-63.
  23. Davis S. Androgen replacement in women: a commentary. J Clin Endocrinol Metab . 1999 Jun;84(6):1886-91.
  24. Turna B, Apaydin E, et al. Women with low libido: correlation of decreased androgen levels with female sexual function index. Int J Impot Res . 2005 Mar-Apr;17(2):148-53.
  25. Buvat J . Androgen therapy with dehydroepiandrosterone. World J Urol . 2003 Nov;21(5):346-55. Epub 2003 Oct 10.
  26. Morley JE, Kaiser F, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA . 1997 Jul 8;94(14):7537-42.
  27. Schwartz AG, Pashko LL. Cancer chemoprevention with the adrenocortical steroid dehydroepiandrosterone and structural analogs. J Cell Biochem Suppl . 1993;17G:73-9.
  28. Yang S, Fu Z, et al. [Anti-mutagenicity activity of dehydroepiandrosterone.] Zhonghua Zhong Liu Za Zhi . 2002 Mar;24(2):137-40.
  29. Yoshida S, Honda A, et al. Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. Steroids . 2003 Jan;68(1):73-83.
  30. Jiang Y, Miyazaki T, et al. Apoptosis and inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway in the anti-proliferative actions of DHEA. J Gastroenterol . 2005 May;40(5):490-7.
  31. Nephew KP, Sheeler CQ, Dudley MD, et al. Studies of dehydroepiandrosterone (DHEA) with the human estrogen receptor in yeast. Mol Cell Endocrinol. 1998;143(1-2):133-42.
  32. Lubet RA, Gordon GB. et al. Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. Cancer Res . 1998 Mar 1;58(5):921-6.
  33. Nyce JW, Magee PN. et al. Inhibition of 1,2-dimethylhydrazine-induced colon tumorigenesis in Balb/c mice by dehydroepiandrosterone. Carcinogenesis . 1984 Jan;5(1):57-62.
  34. Osawa E, Nakajima A, et al. Chemoprevention of precursors to colon cancer by dehydroepiandrosterone (DHEA). Life Sci . 2002 Apr;70(22):2623-30.
  35. Pelissier MA, Trap C, et al. Antioxidant effects of dehydroepiandrosterone and 7alpha-hydroxy-dehydroepiandrosterone in the rat colon, intestine and liver. Steroids . 2004 Feb;69(2):137-44.
  36. Moore MA, Thamavit W, et al. Modifying influence of dehydroepiandrosterone on the development of dihydroxy-di-n-propylnitrosamine-initiated lesions in the thyroid, lung and liver of F344 rats. Carcinogenesis . 1986 Feb;7(2):311-6.
  37. Jedrzejuk D, Medras M, et al. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male . 2003 Sep;6(3):151-6.
  38. Williams JR. The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system, and aging. Lipids . 2000 Mar;35(3):325-31.
  39. Arlt W. Dehydroepiandrosterone and ageing. Best Pract Res Clin Endocrinol Metab . 2004 Sep;18(3):363-80.
  40. Tian WN, Braunstein LD, et al. Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem . 1998 Apr 24;273(17):10609-17.
  41. Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev . 2004 Apr;3(2):171-87.
  42. Rasmuson S, Nasman B, et al. Increased levels of adrenocortical and gonadal hormones in mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord . 2002;13(2):74-9.
  43. Murialdo G, Barreca A, et al. Dexamethasone effects on cortisol secretion in Alzheimer's disease: some clinical and hormonal features in suppressor and nonsuppressor patients. J Endocrinol Invest . 2000 Mar;23(3):178-86.
  44. Solerte SB, Ferrari E, et al. Decreased release of angiogenic peptide VGEF in Alzheimer's disease: recovering effect with insulin and DHEA-S. Dement Geriatr Cogn Disord. 2005;19(1):1-10.
  45. Barrett-Connor E, Khaw KT. Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. N Engl J Med . 1987 Sep 10;317(11):711.
  46. Herrington DM, Gordon GB, et al. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol . 1990 Nov;16(6):862-70.
  47. Hautanen A, Manttari M, et al. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis . 1994 Feb;105(2):191-200.
  48. Barrett-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. Ann NY Acad Sci . 1995 Dec 29;774:259-70.
  49. Feldman HA, Johannes CB, et al. Low dehydroepiandrosterone sulfate and heart disease in middle-aged men: cross-sectional results from the Massachusetts Male Aging Study. Ann Epidemiol . 1998 May;8(4):217-28.
  50. Johannes CB, Stellato RK, et al. Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women's Health Study. J Clin Epidemiol . 1999 Feb;52(2):95-103.
  51. Fukui M, Kitagawa Y, et al. Serum DHEA sulfate concentration and carotid atherosclerosis in men with type 2 diabetes. Atherosclerosis . 2005 Aug;181(2):339-44.
  52. Mazat L, Lafont S, et al. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci USA . 2001 Jul 3;98(14):8145-50.
  53. Gordon GB, Bush DE , et al. Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest . 1988 Aug;82(2):712-20.
  54. Eich DM, Nestler JE, et al. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation . 1993 Jan;87(1):261-9.
  55. Porsova-Dutoit I, Sulcova J, et al. Do DHEA/DHEAS play a protective role in coronary heart disease? Physiol Res . 2000;49(Suppl 1):S43-S56.
  56. Hak AE, Witteman JC, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab . 2002 Aug;87(8):3632-9.
  57. Laughlin GA , Barrett-Connor E. Sexual dimorphism in the influence of advanced aging on adrenal hormone levels: the Rancho Bernardo Study. J Clin Endocrinol Metab . 2000 Oct;85(10):3561-8.
  58. Mitchell LE, Sprecher DL, et al. Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation . 1994 Jan;89(1):89-93.
  59. Slowinska-Srzednicka J, Zgliczynski S, et al. Decreased plasma dehydroepiandrosterone sulfate and dihydrotestosterone concentrations in young men after myocardial infarction. Atherosclerosis . 1989 Oct;79(2-3):197-203.
  60. Ruiz Salmeron RJ, del Arbol JL. et al. [Dehydroepiandrosterone sulfate and lipids in acute myocardial infarct.] Dehidroepiandrosterona-sulfato y lipidos en el infarto agudo de miocardio. Rev Clin Esp . 1992 May;190(8):398-402.
  61. Nestler JE, Clore JN, et al. Dehydroepiandrosterone: the "missing link" between hyperinsulinemia and atherosclerosis? FASEB J . 1992 Sep;6(12):3073-5.
  62. Lasco A, Frisina N, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol . 2001 Oct;145(4):457-61.
  63. Nestler JE, Barlascini CO, et al. Absorption characteristic of breakfast determines insulin sensitivity and carbohydrate tolerance for lunch. Diabetes Care . 1988 Nov;11(10):755-60.
  64. Nestler JE, Clore JN, et al. Metabolism and actions of dehydroepiandrosterone in humans. J Steroid Biochem Mol Biol . 1991;40(4-6):599-605.
  65. Kurzman ID, MacEwen EG, et al. Reduction in body weight and cholesterol in spontaneously obese dogs by dehydroepiandrosterone. Int J Obes . 1990 Feb;14(2):95-104.
  66. Khalil A, Fortin JP, et al. Age-related decrease of dehydroepiandrosterone concentrations in low density lipoproteins and its role in the susceptibility of low density lipoproteins to lipid peroxidation. J Lipid Res . 2000 Oct;41(10):1552-61.
  67. Villareal DT, Holloszy JO, et al. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf) . 2000 Nov;53(5):561-8.
  68. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA . 2004 Nov 10;292(18):2243-8.
  69. Roberts E, Bologa L, et al. Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice. Brain Res . 1987 Mar 17;406(1-2):357-62.
  70. Flood JF, Smith GE, et al. Dehydroepiandrosterone and its sulfate enhance memory retention in mice. Brain Res . 1988 May 3;447(2):269-78.
  71. Kalmijn S, Launer LJ, et al. A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly. J Clin Endocrinol Metab . 1998 Oct;83(10):3487-92.
  72. Ferrari E, Cravello L, et al. Age-related changes of the hypothalamic-pituitary-adrenal axis: pathophysiological correlates. Eur J Endocrinol . 2001 Apr;144(4):319-29.
  73. Herbert J. Neurosteroids, brain damage, and mental illness. Exp Gerontol . 1998 Nov;33(7-8):713-27.
  74. Ferrari E, Mirani M, et al. Cognitive and affective disorders in the elderly: a neuroendocrine study. Arch Gerontol Geriatr Suppl . 2004;(9):171-82.
  75. Yaffe K, Ettinger B, et al. Neuropsychiatric function and dehydroepiandrosterone sulfate in elderly women: a prospective study. Biol Psychiatry . 1998 May 1;43(9):694-700.
  76. van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology (Berl) . 2003 Jan;165(2):97-110.
  77. Bloch M, Schmidt PJ et al. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry . 1999 Jun 15;45(12):1533-41.
  78. Morales AJ, Nolan JJ, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab . 1994 Jun;78(6):1360-7.
  79. Schmidt PJ, Daly RC, et al. DHEA monotherapy in midlife-onset and minor depression. Arch Gen Psychiatry. 2005 Feb;62(2):154-62.
  80. Kameda W, Daimon M, et al. Association of decrease in serum DHEA-S levels with the progression to type 2 diabetes in men of a Japanese population: the Funagata study. Metabolism . 2005 May;54(5):669-76.
  81. Dhatariya K, Bigelow ML, et al. Effect of DHEA replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes . 2005 Mar;54(3):765-9.
  82. Dyner TS, Lang W, et al. An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease. J Acquir Immune Defic Syndr . 1993 May;6(5):459-65.
  83. Jacobson MA, Fusaro RE, et al. Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200-499. J Infect Dis . 1991 Nov;164(5):864-8.
  84. Ferrando SJ, Rabkin JG, et al. Dehydroepiandrosterone sulfate (DHEAS) and testosterone: relation to HIV illness stage and progression over one year. J Acquir Immune Defic Syndr . 1999 Oct 1;22(2):146-54.
  85. Christeff N, Gherbi N. et al. Serum cortisol and DHEA concentrations during HIV infection. Psychoneuroendocrinology . 1997;22(Suppl 1):S11-S18.
  86. Christeff N, Melchior JC. et al. Correlation between increased cortisol:DHEA ratio and malnutrition in HIV-positive men. Nutrition . 1999 Jul;15(7-8):534-9.
  87. Christeff N, Nunez EA. et al. Changes in cortisol/DHEA ratio in HIV-infected men are related to immunological and metabolic perturbations leading to malnutrition and lipodystrophy. Ann NY Acad Sci . 2000;917:962-70.
  88. Dos Santos CD, Toldo MP, et al. Trypanosoma cruzi: the effects of DHEA treatment during experimental infection. Acta Trop. 2005 Aug;95(2):109-15.
  89. Labrie F, Diamond P, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab . 1997 Oct;82(10):3498-505.
  90. Haden ST , Glowacki J, et al. Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. Calcif Tissue Int . 2000 Jun;66(6):414-8.
  91. Carlstrom K, Brody S. et al. Dehydroepiandrosterone sulphate and dehydroepiandrosterone in serum: differences related to age and sex. Maturitas . 1988 Dec;10(4):297-306.
  92. Taelman P, Kaufman JM, et al. Persistence of increased bone resorption and possible role of dehydroepiandrosterone as a bone metabolism determinant in osteoporotic women in late post-menopause. Maturitas . 1989 Mar;11(1):65-73.
  93. Brody S, Carlstrom K. et al. Adrenocortical steroids, bone mineral content and endometrial condition in post-menopausal women. Maturitas . 1982 Aug;4(2):113-22.
  94. Nordin BE, Robertson A, et al. The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. J Clin Endocrinol Metab . 1985 Apr;60(4):651-7.
  95. Deutsch S, Benjamin F. et al. The correlation of serum estrogens and androgens with bone density in the late postmenopause. Int J Gynaecol Obstet . 1987 Jun;25(3):217-22.
  96. Wild RA, Buchanan JR, et al. Declining adrenal androgens: an association with bone loss in aging women. Proc Soc Exp Biol Med . 1987 Dec;186(3):355-60.
  97. Barrett-Connor E, Kritz-Silverstein D. et al. A prospective study of dehydroepiandrosterone sulfate (DHEAS) and bone mineral density in older men and women. Am J Epidemiol . 1993 Jan 15;137(2):201-6.
  98. Parker LN, Levin ER, et al. Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab . 1985 May;60(5):947-52.
  99. Lephart ED, Baxter CR, et al. Effect of burn trauma on adrenal and testicular steroid hormone production. J Clin Endocrinol Metab . 1987 Apr;64(4):842-8
  100. Wade CE, Lindberg JS, et al. Upon-admission adrenal steroidogenesis is adapted to the degree of illness in intensive care unit patients. J Clin Endocrinol Metab . 1988 Aug;67(2):223-7.
  101. Glaser JL, Brind JL, et al. Elevated serum dehydroepiandrosterone sulfate levels in practitioners of the Transcendental Meditation (TM) and TM-Sidhi programs. J Behav Med . 1992 Aug;15(4):327-41.
  102. McCraty R, Barrios-Choplin B, et al. The impact of a new emotional self-management program on stress, emotions, heart rate variability, DHEA and cortisol. Integr Physiol Behav Sci . 1998 Apr;33(2):151-70.
  103. Kalman DS, Colker CM, et al. A randomized, double-blind, placebo-controlled study of 3-acetyl-oxo-dehydroepiandreosterone in healthy overweight adults. Curr Therap Res . 2000;61(7):435-42.
  104. Sulcova J, Hill M, et al. Effects of transdermal application of 7-oxo-DHEA on the levels of steroid hormones, gonadotropins and lipids in healthy men. Physiol Res . 2001;50(1):9-18.
  105. Zenk JL, Kuskowsi MA. The use of 3-acetyl-7-oxo-dehydroepiandrosterone for augmenting immune response in the elderly. Presented at meeting of FASEB, April 17, 1994.
  106. Cameron DR , Braunstein GD. The use of DHEA therapy in clinical practive. Treat Endocrinol . 2005;4(2):95-114.